Hematopoietic stem-cell transplantation for Hodgkin's disease (HD): current status

References

• Urba WJ, Longo DL. Hodgkin's disease. New Engl .7 Med 1992;326: 678–87.
   Google Scholar
• Aisenberg AC. Problems in Hodgkin's disease management.Blood 1999;93:761–79.
   PubMed Web of Science ®Google Scholar
• Mauch PM. Controversies in the management of early-stage Hodgkin's disease. Blood 1994;83:318–29.
   PubMed Web of Science ®Google Scholar
• Bonfante V, Santoro A, Viviani S et al. Outcome of patientswith Hodgkin's disease failing after primary MOPP-ABVD. Clin °nevi 1997;15:528–34.
   PubMed Web of Science ®Google Scholar
• Lohri A, Barnett M, Fairey RN et al. Outcome of treatmentof first relapse of Hodgkin's disease after primary chemotherapy: identification of risk factors from the British Columbia experience 1970 to 1988. Blood 1991;77:2292–8.
   PubMed Web of Science ®Google Scholar
• Johnston LJ, Horning SJ. Autologous hematopoietic stem cell transplantation in Hodgkin's disease. Biol Blood Marrow Transplant 2000;6:289–300.
   PubMed Web of Science ®Google Scholar
• Forman SJ. Role of high-dose therapy and stem cell trans-plantation in the management of Hodgkin's disease. Am Soc Clin Oncol Ed Book 1997:244–7.
   Google Scholar
• Linch DC, Goldstone AH. High-dose therapy for Hodgkin's disease. Br y Haematol 1999;107:685–90.
   PubMed Web of Science ®Google Scholar
• Bierman PJ, Vose JM, Armitage JO. Autologous transplanta-tion for Hodgkin's disease: coming of age? Blood 1994; 83:1161–4.
   Google Scholar
• Linch DC, Winfield D, Goldstone AH et al. Dose intensifi-cation with autologous bone marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomized trial. Lancet 1993;341:1051–4.
   PubMed Web of Science ®Google Scholar
• Schmitz N, Sextro M, Pfistner B et al. High-dose therapy (HDT) followed by hematopoietic stem cell transplantation (HSCT) for relapsed chemosensitive Hodgkin's disease (HD): final results of a randomized GHSG and EBMT trial. Proc Am Soc Clin [abstract] Oncol 1999;18:2a.
   Google Scholar
• Lazarus HM, Rowlings PA, Zhang M et al. Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. 7 Clin Oncol 1999;17:539–45.
   Web of Science ®Google Scholar
• Reece DE, Barnett MJ, Shepherd JD et al. High-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) with or without cisplatin (CBV ± P) and auto-logous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy. Blood 1995;86:451–6.
   PubMed Web of Science ®Google Scholar
• Sweetenham JW, Carella AM, Taghipour G et al. High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: results in 175 patients reported to the European Group for Blood and Marrow Transplantation. 7 Clin Oncol 1999;17: 3101–9.
   Google Scholar
• Josting A, Rueffer U, Franklin J et al. Prognostic factors and treatment outcome in primary progressive Hodgkin lym-phoma: a report from the German Hodgkin Lymphoma Study Group. Blood 2000;96:1280–6.
   PubMed Web of Science ®Google Scholar
• Andre M, Henry-Amar M, Pico JL et al. Comparison of high-dose therapy and autologous stem cell transplantation with conventional therapy for Hodgkin's disease induction failure: a case-control study. 7 Clin Oncol1999;17:222–9.
   PubMed Web of Science ®Google Scholar
• Lazarus HM, Loberiza FR, Zhang MJ et al. Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR). Bone Marrow Transplant 2001;27:387–96.
   PubMed Web of Science ®Google Scholar
• Sweetenham JW, Taghipour G, Milligan D et al. High-dose therapy and autologous stem cell rescue for patients with Hodgkin's disease in first relapse after chemotherapy: results from the EBMT. Bone Marrow Transplant 1997; 20:745–52.
   PubMed Web of Science ®Google Scholar
• Brice P, Bouabdallah, Moreau P et al. Prognostic factors for survival after high-dose therapy and autologous stem celltransplantation for patients with relapsing Hodgkin's dis-ease: analysis of 280 patients from the French registry. Bone Marrow Transplant 1997;20:21–6.
   PubMed Web of Science ®Google Scholar
• Bierman PJ et al. High-dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin's disease patients following first relapse after chemotherapy. Ann Oncol 1996;7:151–6.
   PubMed Web of Science ®Google Scholar
• Reece DE, Connors JM, Spinelli JJ et al. Intensive therapy with cyclophosphamide, carmustine, etoposide ± cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. Blood 1994;83:1193–9.
   PubMed Web of Science ®Google Scholar
• Chopra R, McMillan AK, Linch DC et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease: a single-center 8-year study of 155 patients. B1ood1993;81:1137–45.
   Google Scholar
• Sureda A, Arranz R, Carreras E et al. Autologous stem-cell transplantation for Hodgkin's disease: results and prognos-tic factors in 494 patients from the Grupo Espanol de Linfomas/Transplante autologo de Medula Osea Spanish Cooperative Group. 7 Clin Oncol 2001;19: 1395–1404.
   Google Scholar
• Nademanee A, O'Donnell MR, Snyder DS et al. High-dose chemotherapy with or without total body irradiation fol-lowed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: results in 85 patients with analysis of prognostic factors. Blood 1995;85: 1381–90.
   Google Scholar
• Horning SJ, Chao NJ, Negrin RS et al. High-dose therapy and autologous hematopoietic progenitor cell transplanta-tion for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. Blood 1997;89:801–13.
   PubMed Web of Science ®Google Scholar
• Yuen AR, Rosenberg SA, Hoppe RT et al. Comparison between conventional salvage therapy and high-dose ther-apy with autografting for recurrent or refractory Hodgkin's disease. Blood 1997;89:814–22.
   PubMed Web of Science ®Google Scholar
• Popat U, Andersson BS, Van Besien K et al. ABMT in recur-rent or refractory HD: long term results [abstract]. Blood 1997;90:115a.
   Google Scholar
• Bierman PJ, Bagin RG, Jagannath S et al. High-dose chemotherapy followed by autologous stem cell rescue in Hodgkin's disease: long-term follow-up in 128 patients. Ann Oncol 1993;4:767–73.
   PubMed Web of Science ®Google Scholar
• Hasenclever D, Diehl V for the International Prognostic Factors Project on Advanced Hodgkin's disease. A prognos-tic score for advanced Hodgkin's disease. N Engl 7 Med 1998;339:1506–14.
   PubMedGoogle Scholar
• Lynch JC, Bierman PJ, Bociek G et al. The Hodgkin's disease Prognostic Index predicts outcome of autologous stem cell transplantation (ASCT) [abstract]. Proc Am Soc Clin Oncol 2001;20:5a.
   Google Scholar
• Majolino I, Pearce R, Taghipour G et al. Peripheral blood stem-cell transplantation versus autologous bone marrow transplantation in Hodgkin's disease and non-Hodgkin's lymphomas: a new matched-pair analysis of the EuropeanGroup for Blood and Marrow Transplantation. y Clin Oncol 1997;15:509–17.
   PubMed Web of Science ®Google Scholar
• CareIla AM, Prencipe E, Pungolino E et al. Twelve years experience with high-dose therapy and autologous stem cell transplantation for high-risk Hodgkin's disease patients in first remission after MOPP/ABVD chemotherapy. Leuk Lymph 1996;21:63–70.
   PubMed Web of Science ®Google Scholar
• Nademanee A, Molina A, Fung H et al. High-dose chemo/radiotherapy and autologous bone marrow or stem cell transplantation for poor-risk, advanced-stage Hodgkin's disease during first partial or complete remission. Biol Blood Marrow Transplant 1999;5:292–8.
   PubMedGoogle Scholar
• Moreau P, Fleury J, Brice P et al. Early intensive therapy with autologous stem cell transplantation in advanced Hodgkin's disease: retrospective analysis of 158 cases from the French Registry. Bone Marrow Transplant 1998; 21:787–93.
   PubMed Web of Science ®Google Scholar
• Schmitz N, Hasenclever D, Brosteanu 0 et al. Early high-dose therapy to consolidate patients with high-risk Hodgkin's disease in first complete remission? Results of an EBMT/GHSG matched pair analysis [abstract]. Blood 1995;86:439a.
   Google Scholar
• Sureda A, Mataix R, Hernandez-Navarro F et al. Autologous stem cell transplantation for poor prognosis Hodgkin's dis-ease in first complete remission: a retrospective study from the Spanish GEL-TAMO cooperative group. Bone Marrow Transplant 1997;20:283–8.
   PubMed Web of Science ®Google Scholar
• Federico M, ClO V, Carella A, EBMT/ANZLG/Intergroup HDO1 trial: High-dose therapy and autologous stem cell transplantation vs conventional therapy for patients with advanced Hodgkin's disease responding to first-line ther-apy: analysis of clinical characteristics of 51 patients enrolled in the HDO1 protocol [abstract]. Leukemia 1996;10 (Suppl. 2):s69.
   Google Scholar
• Lancet JE, Rapoport AP, Brasacchio R et al. Autotrans-plantation for relapsed or refractory Hodgkin's disease: long-term follow-up and analysis of prognostic factors. Bone Marrow Transplant 1998;22:265–71.
   PubMed Web of Science ®Google Scholar
• Hoppe RT. Radiation therapy as a component of high-dose salvage strategies for Hodgkin's disease. Ann Oncol 1998; 9:S87—S90.
   Web of Science ®Google Scholar
• Hancock SL. Secondary neoplasms after Hodgkin's disease. Am Soc Hematol Ed Program Book 2000;212–14.
   Google Scholar
• van Leuween FE, Klokman WJ, Hagenbeek A et al. Second cancer risk following Hodgkin's disease: a 20-year follow-up study. y Clin Oncol 1994;12:312–25.
   PubMedGoogle Scholar
• Swerdlow AJ, Barber JA, Vaughan Hudson G et al. Risk of second malignancy after Hodgkin's disease in a collabora-tive British Cohort: the relation to age at treatment. y Clin Oncol 2000;18:498–509.
   Google Scholar
• Andre M, Henry-Amar M, Blaise D et al. Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's disease. Blood 1998; 92:1933–40.
   PubMed Web of Science ®Google Scholar
• Gianni AM, Bregni M, Siena S et al. High-dose chemother-apy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl med 1997;336:1290–7.
   PubMed Web of Science ®Google Scholar
• Tarella C, Liberati M, Vitolo U et al. Multicenter evaluation of the high-dose sequential (HDS) chemotherapy regimen as salvage treatment for refractory/relapsed Hodgkin's disease [abstract]. Bone Marrow Transplant 2000;25:Supp1.1 S126.
   Google Scholar
• Santoro A, Bredenfeld H, Devizzi L et al. Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study. y Clin On col 2000;18:2615–19.
   Google Scholar
• Donnelly GB, Filippa D, Moskowitz CH et al. Increased treatment failure in patients with CD20 positive classic Hodgkin's disease (HD) [abstract]. Blood 1999; 94:598a
   Google Scholar
• Vose JL. MAb therapy: the use of antiCD20 abs. Therapeutic uses of MAbs directed against CD20. Cytotherapy 2000;2: 455–62.
   Google Scholar
• Redman J, Hagemeister F, McLaughlin P et al. a-Interferon treatment of Hodgkin's disease [abstract]. Proc Am Soc Clin Oncol1990;9:256a.
   Google Scholar
• Aviles A, Diaz-Maqueo JC, Talavera A et al. Maintenance therapy with interferon alfa 2b in Hodgkin's disease. Leuk Lymph 1998;30:651–6.
   PubMed Web of Science ®Google Scholar
• Bollard CM, Aguilar LK, Roskrow MA et al. Cytotoxic T-lymphocyte therapy for relapsed EBV+ HD [abstract]. Cytotherapy 2000;2:318a
   Google Scholar
• Gajewski JL, Phillips GL, Sobocinski KA et al. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease. y Clin Oncol1996;14:572–8.
   PubMed Web of Science ®Google Scholar
• Anderson JE, Litzow MR, Appelbaum FR et al. Allogeneic, syngeneic and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience. y Clin Oncol 1993;11:2342–50.
   PubMed Web of Science ®Google Scholar
• Milpied N, Fielding AK, Pearce R et al. for the European Group for Blood and Marrow Transplantation: Allogeneic bone marrow transplant is not better than autologous trans-plant for patients with relapsed Hodgkin's disease. y Clin Oncol 1996;14:1291–6.
   PubMed Web of Science ®Google Scholar
• Akpek G, Ambinder RF, Piantadosi S et al. Long-term follow-up of bone marrow transplantation for Hodgkin's disease: evidence for a graft-versus-tumor effect [abstract]. Proc Am Soc Clin Oncol 1999;18:53a.
   Google Scholar
• Champlin R, Khouri I, Kornblau S, et al. Allogeneic hematopoietic transplantation as adoptive immunotherapy: induction of graft-vs.-malignancy as primary therapy. Hem atol Oncol Clin N Am 1999;13:1041–57.
   PubMed Web of Science ®Google Scholar
• Martino R, Sierra J. Allogeneic hematopoietic stem cell transplantation after immunosuppressive but non-myeloab-lative conditioning: `miniallografts' are no small matter. Haematologica 1998;83:865–7.
   PubMed Web of Science ®Google Scholar
• Robinson SP, Mackinnon S, Goldstone AH et al. Higher than expected transplant-related mortality and relapse following non-myeloablative stem cell transplantation for lymphoma adversely effects progression-free survival [abstract]. Blood 2000;96:554a.
   PubMed Web of Science ®Google Scholar
• Porter DL, Luger SM, Duffy KM, et al. Allogeneic cell ther-apy for patients who relapse after autologous stem cell transplantation. Biol Blood Marrow Transplant 2001;7:230–8.
   PubMed Web of Science ®Google Scholar
• Carella AM, Cavaliere M, Lerma E et al. Autografting followed by non-myeloablative immunosuppressive chemo-therapy and allogeneic peripheral-blood hematopoieticstem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma. 7 Clin Oncol2000;18:3918–24.
   PubMed Web of Science ®Google Scholar
• Dreger P, Uharek L, Glass B, et al. Adoptive immunotherapyfor treatment of Hodgkin's disease: proof of principle [abstract]. Bone Marrow Transplant 2000;25:Supp1.1 S173.
   Google Scholar